Abstract
Teriparatide is a drug for the treatment of osteoporosis which is licensed for use for up to 24 months. There is little experience with retreatment. The aim of this study was to evaluate, in three patients with severe secondary osteoporosis, the response to a second cycle of teriparatide regarding bone mineral density (BMD) and osteocalcin. Case 1 : A 62-year-old woman with multiple vertebral fractures has received corticoids for a long time. After starting teriparatide, her BMD and osteocalcin increased. She then received ibandronate for 3 years but her BMD declined. After a second treatment with teriparatide, her BMD increased again (18%). Case 2 : A 60-year-old woman with severe osteoporosis in lumbar spine (LS) (T-score − 4.5) had received corticoids for a long time and had celiac disease. After starting teriparatide, her BMD improved by 11.7%. She then received zoledronic acid for 15 months, but bone density decreased, so she was retreated with teriparatide. BMD had a slightly higher increase than after the first cycle (12.6%). Case 3 : A 60-year-old woman consulted for osteoporosis (LS T-score − 5.3), several fractures, and hyperthyroidism. She started teriparatide with improvement in BMD (39%). After 24 months, she received ibandronate for 1 year, but as her BMD declined, she was retreated with teriparatide. BMD showed an increase of 15%. The indication of a second cycle of treatment with teriparatide in three patients was effective in increasing BMD. Additional studies are needed to further identify the benefits and safety of retreatment with teriparatide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vokes TJ, Favus MJ (2010) Osteoporosis update. Translational Endocrinology & Metabolism 1(1):9–55
Boonen S, Marín F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93(3):852–860
Finkelstein JS, Wyland BZ, Burnett-Bowie SA et al (2009) Effect of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 94(7):2495–2501
Silverman SL, Nasser K (2011) Teriparatide update. Rheum Dis Clin N Am 37:471–477
Cosman F, Nieves JW, Zion M et al (2009) Retreatment with teriparatide one year after the first teriparatide course in patients on continues long-term alendronate. J Bone Miner Res 24(6):1110–1115
Bilezikian JP, Rubin MR (2006) Combination/sequential therapies for anabolic and antiresortive skeletal agents for osteoporosis. Current Osteoporosis Reports 4:5–13
Uihlen AV, Leder BZ (2012) Anabolic therapies for osteoporosis. Endocrinol Metab Clin N Am 41:507–525
Grover A, LeBoff M (2013) Osteoporosis: prevention and treatment. Combination therapy. Endotext http://www.endotext.org/chapter/osteoporosis-prevention-and-treatment/
Ettinger B, San Martín J, Crans G (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19(5):745–751
Tournis S, Dede A et al (2015) Effects of teriparatide retreatment in a patient with β-thalassemia major. Transfusion 55(12):2905–2910
Acknowledgements
The authors thank the invaluable help of Susana Carballo for editing the English language of the manuscript and Federico Matorra for his assistance with the graphics used in this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Mana, D.L., Zanchetta, M.B. & Zanchetta, J.R. Retreatment with teriparatide: our experience in three patients with severe secondary osteoporosis. Osteoporos Int 28, 1491–1494 (2017). https://doi.org/10.1007/s00198-016-3869-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-016-3869-z